Question 1

What is combined oxidative phosphorylation defect type 11?

Accepted Answer

Combined oxidative phosphorylation defect type 11 is a condition that disrupts the body’s energy production due to mutations in the RMND1 gene. It affects multiple organ systems, with many individuals exhibiting severe issues such as respiratory failure, lactic acidosis, and renal insufficiency. The condition is inherited in an autosomal recessive pattern and is very rare, affecting fewer than 1 in a million people. Although symptoms are present from early life, the overall course and severity can vary considerably.

Question 2

What are the symptoms of combined oxidative phosphorylation defect type 11?

Accepted Answer

The clinical picture of combined oxidative phosphorylation defect type 11 is dominated by characteristic findings including respiratory failure, lactic acidosis, increased circulating lactate, and renal insufficiency, all of which are consistently observed. Many affected individuals also present with generalized hypotonia, while other features such as lethargy, tongue fasciculations, and hyporeflexia occur in a majority of cases. In some instances, patients may exhibit polyhydramnios during pregnancy, and a subset experience cardiomyopathy, myoclonus, areflexia, hepatomegaly, or peripheral neuropathy. Not all individuals experience all features, and severity varies considerably, reflecting the variable expressivity of the condition.

Question 3

What causes combined oxidative phosphorylation defect type 11?

Accepted Answer

This disorder is caused by pathogenic variants in the RMND1 gene, which plays a critical role in mitochondrial function and energy production. It is inherited in an autosomal recessive pattern, meaning that an affected individual has received one mutated copy of the gene from each parent. This condition is more common when parents share a common ancestor, as the likelihood that both carry the same rare variant is increased. Given these inheritance implications, families are encouraged to seek genetic counseling to better understand recurrence risks and family planning options. Associated genes include RMND1.

Question 4

How is combined oxidative phosphorylation defect type 11 inherited?

Accepted Answer

combined oxidative phosphorylation defect type 11 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is combined oxidative phosphorylation defect type 11?

Accepted Answer

combined oxidative phosphorylation defect type 11 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is combined oxidative phosphorylation defect type 11 diagnosed?

Accepted Answer

Diagnosis of combined oxidative phosphorylation defect type 11 is confirmed through molecular genetic testing that identifies pathogenic variants in RMND1. Clinical evaluation that includes assessment of characteristic findings such as respiratory distress, lactic acidosis, and renal insufficiency supports the diagnosis. Because many of these features can be seen in other conditions, molecular genetic testing is essential to distinguish this disorder from other similar presentations.

Question 7

Are there treatments for combined oxidative phosphorylation defect type 11?

Accepted Answer

Currently, management focuses on supportive care and symptom management, as no treatments are specifically approved for combined oxidative phosphorylation defect type 11. Treatment is tailored to the individual and typically involves a multidisciplinary team to address respiratory, renal, and metabolic complications. Regular surveillance is an essential part of long-term care, helping to identify potential complications early, and may include periodic assessments by specialists. Patients are advised to discuss treatment options with their healthcare team to determine the most appropriate supportive interventions, and genetic counseling is recommended to assist with family planning considerations.

Question 8

What complications can arise from combined oxidative phosphorylation defect type 11?

Accepted Answer

Combined oxidative phosphorylation defect type 11 can lead to serious complications such as respiratory failure, lactic acidosis, and renal insufficiency. These complications can significantly affect daily life and may require ongoing medical support. Regular monitoring and management by a healthcare team are essential to address these issues as they arise.

Question 9

How does combined oxidative phosphorylation defect type 11 affect daily life for patients?

Accepted Answer

Living with combined oxidative phosphorylation defect type 11 can be challenging due to symptoms like generalized hypotonia and lethargy. Patients may need assistance with daily activities and require regular medical check-ups to manage their health. Supportive care and a multidisciplinary approach can help improve their quality of life.

Question 10

What is the prognosis for someone with combined oxidative phosphorylation defect type 11?

Accepted Answer

The prognosis for individuals with combined oxidative phosphorylation defect type 11 varies widely. Factors such as the severity of symptoms and access to specialized care can influence outcomes. While many patients face significant challenges, advancements in supportive care have improved both the quality and duration of life for some individuals.

Question 11

Are there specific specialists that families should consult for combined oxidative phosphorylation defect type 11?

Accepted Answer

Families dealing with combined oxidative phosphorylation defect type 11 should consider consulting specialists who are familiar with mitochondrial disorders. A multidisciplinary team may include geneticists, neurologists, and metabolic specialists to provide comprehensive care. Regular assessments by these experts can help manage symptoms and monitor for potential complications.

Organ System	Phenotype Count	Example Features
Brain and nerves	8	Seizure, Cerebral cortical atrophy, Tongue fasciculations
Kidneys and urinary system	5	Renal hypoplasia, Reduced kidney function (renal insufficiency), Renal tubular acidosis
Muscles	5	Myopathy, Cerebral cortical atrophy, Severe muscular hypotonia
Digestive system	4	Hepatic steatosis, Decreased liver function, Enlarged liver (hepatomegaly)
Ears	1	Hearing loss (hearing impairment)
Lungs and breathing	1	Respiratory failure
Lab test results	1	Increased circulating lactate concentration
Heart and blood vessels	1	Heart muscle disease (cardiomyopathy)

Kisho

combined oxidative phosphorylation defect type 11

Overview

Clinical Presentation

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

combined oxidative phosphorylation defect type 11

Overview

Clinical Presentation

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation defect type 11?

What are the symptoms of combined oxidative phosphorylation defect type 11?

What causes combined oxidative phosphorylation defect type 11?

How is combined oxidative phosphorylation defect type 11 inherited?

How rare is combined oxidative phosphorylation defect type 11?

How is combined oxidative phosphorylation defect type 11 diagnosed?

Are there treatments for combined oxidative phosphorylation defect type 11?

What complications can arise from combined oxidative phosphorylation defect type 11?

How does combined oxidative phosphorylation defect type 11 affect daily life for patients?

What is the prognosis for someone with combined oxidative phosphorylation defect type 11?

Are there specific specialists that families should consult for combined oxidative phosphorylation defect type 11?

Explore clinical features

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications